Bundibugyo Ebola Outbreak Tops 1,150 Cases as Disease Crosses Into Europe

Jul 07, 2026

people in white robe walking on sidewalk during daytime — Photo by Gani Nurhakim on Unsplash

The Bundibugyo Ebola outbreak in the Democratic Republic of the Congo and Uganda continues to escalate. As of 25 June, the DRC Ministry of Health had confirmed 1,155 cases and 304 deaths, with Uganda reporting no new cases since 5 June. The outbreak has now reached Europe. France confirmed its first case on 24 June in a healthcare worker who had been deployed to the DRC, joining an earlier case medically evacuated to Germany in May. However, The European Centre for Disease Prevention and Control (ECDC) assesses the risk to the EU/EEA general population as very low.

The response to the outbreak is hampered by the absence of an approved vaccine or treatment for the Bundibugyo strain; the existing Ervebo vaccine, effective against the more common Zaire species, has been judged by WHO to lack sufficient evidence of cross-protection. Three vaccine candidates (from IAVI, Moderna, and Oxford) are being fast-tracked through CEPI funding, alongside trials of remdesivir and two monoclonal antibody therapies.

The Ebolaviruses are reverse RNA viruses and are subject to a high rate of mutation - and the emergence of different strains.

Hantavirus: Nebraska Quarantine Concludes After Six Weeks

The hantavirus story linked to the cruise ship MV Hondius has reached its resolution. The last eight American passengers completed their 42-day quarantine at the National Quarantine Unit in Omaha, Nebraska, on 22 June, bringing to a close what HHS (US Department of Health and Human Services) described as a successful response. The global cluster ultimately comprised 11 confirmed and probable cases and three deaths, with a delayed case also confirmed in a Spanish evacuee weeks after disembarkation.

The Andes virus strain involved is unusual among hantaviruses in its capacity, in rare cases, for limited person-to-person transmission via prolonged close contact, the reason for the unusually long and cautious monitoring period. However, compared to other viruses, human-to-human transmission is extremely low and required prolonged close contact (R0 ~ 1, barely enough to sustain an epidemic, compared to measles virus R0 >12 and seasonal flu R0 ~ 1.5).

white and green syringe on white surface — Photo by Iván Díaz on Unsplash

AI-Designed Pan-Coronavirus Vaccine: Cambridge Team Sets Sights on Phase II

Cambridge spin-out DIOSynVax’s pEVAC-PS, the first vaccine whose active component was designed entirely by AI to pass human testing, remains safe and well-tolerated across all four Phase I dose levels, with cross-reactive antibodies detected against SARS-CoV-2, SARS, and related bat sarbecoviruses. Professor Jonathan Heeney has confirmed the team is now adapting the same AI antigen-design pipeline for influenza and Ebola-family vaccines. Published pre-clinical work already shows a pan-H5 avian influenza candidate generating neutralising antibodies against all 12 tested clades (distinct viral evolutionary branches) in mice.

The platform’s thermostability and needle-free delivery offer genuine advantages for low-resource deployment, but pEVAC-PS remains a commercially structured product of a UK university spin-out, funded through Innovate UK. No access framework has yet been described for Phase II or beyond.

UK Healthy Life Expectancy Falls to Lowest on Record — and the UK Now Trails Most Peer Nations

The Health Foundation’s briefing for the 1 June Second Reading of the Health Bill lays out the starkest picture yet of declining UK population health. Healthy life expectancy fell by roughly two years over the decade 2012–14 to 2022–24, to 60.7 years for men and 60.9 for women — with steep declines across England, Scotland, and Wales. As a result, the UK has fallen from 14th to 20th among 21 comparable high-income countries; only the United States now scores lower. The UK is one of just five of those 21 countries where healthy life expectancy fell at all between 2011 and 2021, and recorded the second-steepest decline of any of them.

The inequality gradient is severe and widening. The gap in healthy life expectancy between the most and least deprived deciles in England now stands at 19.4 years for men and 20.3 years for women. In Scotland, women in the least deprived areas can expect 24.2 more years of healthy life than women in the most deprived areas. The Health Foundation projects roughly 700,000 more working-age people will be living with major illness by 2040 — 80% of them in more deprived areas.

The health gap is widening and closely reflects the widening wealth inequalities. While life-expectancy might not be affected, the poor can expect to spend more of their later years in significant ill-health. The rich get richer while the poor become sicker - an effect of the World’s hideously skewed, and unfair, wealth distribution.

AMR in England: Resistant Infections Up 13% as Inequality Gap Widens

UKHSA’s ESPAUR 2024–25 report confirms that drug-resistant infections in England rose 13.1% over the five years to 2024, even as antibiotic consumption fell 2% from pre-pandemic levels. Concerning developments include continued increases in resistant E. coli, the emergence of ceftriaxone-resistant gonorrhoea, and dual-resistant Mycoplasma genitalium — both signalling the narrowing of treatment options for common infections.

This year’s report makes the social gradient explicit for the first time: the rate of resistant bacteraemia is 47% higher in the most deprived areas of England compared with the least deprived, a gap that has widened by 18% since 2019. AMR, like so much else in this newsletter, is not distributed randomly, and the UK’s own surveillance data now confirms it.

ECDC Warns of Earlier, Larger Dengue and Chikungunya Risk Across the EU

The European Centre for Disease Prevention and Control has flagged an unusually early start to this year’s chikungunya transmission season in mainland Europe, with the first locally acquired cases reported in late May/early June, weeks earlier than the typical July–August onset. ECDC attributes the early start to elevated pressure from imported cases, particularly from the Indian Ocean region, in areas where the Asian tiger mosquito (Aedes albopictus) - the vector for the chikungunya, dengue and zika viruses - is now well established.

The role of climate change

The trend reflects a broader pattern of northward arboviral expansion. A 2025 study found that recent climate change has measurably accelerated Ae. albopictus range expansion in France, with the dengue transmission risk zone extending from Mediterranean coastal regions to northern Spain and western France; researchers project that by the 2050s, arbovirus transmission could become possible as far north as Scandinavia. France recorded a record 228 locally acquired chikungunya cases in 2025 — compared with just 32 cumulative locally transmitted cases across the entire 2010–2024 period — including an unprecedented cluster in Alsace, which ECDC called “an exceptional occurrence at this latitude.” Italy recorded 213 autochthonous (indigenous, locally acquired) dengue cases in 2024 alone.

Why is the Aedes albopictus mosquito so important?

Aedes albopuctus has several biological characteristics that make it far better suited to temperate European expansion:

Its eggs undergo diapause — a dormancy state triggered by shortening day length — allowing them to survive cold winters
It tolerates a broader temperature range and is active at lower ambient temperatures
It breeds readily in small artificial water containers (tyres, flower pot saucers, gutters, garden water features) — making urban environments particularly hospitable
It is an opportunistic feeder that bites a wide range of hosts, including birds, maintaining enzootic (constantly present in a locality) cycles that can amplify transmission risk

The combination of these traits — cold tolerance, urban adaptability, broad host range, and competence for multiple pathogens — is why climate-driven northward range expansion of Ae. albopictus represents a different public health challenge from most vector-borne disease risks previously encountered in northern and central Europe. It is also spreading northwards in the United States.

Vector-borne disease expansion driven by climate change does not respect borders, but its public health burden falls hardest on regions with the weakest mosquito surveillance and vector control infrastructure — often the same lower-income municipalities least equipped to fund proactive Aedes control programmes.

Asclepius

Discussion about this post

Ready for more?